Definium Therapeutics shares rise after positive DT120 anxiety study
Definium Therapeutics reported positive topline results from its Phase 3 study of DT120, an orally disintegrating tablet for adults with generalized anxiety disorder.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.